Reversible decrease of portal venous flow in cirrhotic patients: a positive side effect of sorafenib.

por Romain Coriat, Hervé Gouya, Olivier Mir, Stanislas Ropert, Olivier Vignaux, Stanislas Chaussade, Philippe Sogni, Stanislas Pol, Benoit Blanchet, Paul Legmann, François Goldwasser
Publicado 2011

Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma.

por Olivier Mir, Romain Coriat, Benoit Blanchet, Jean-Philippe Durand, Pascaline Boudou-Rouquette, Judith Michels, Stanislas Ropert, Michel Vidal, Stanislas Pol, Stanislas Chaussade, François Goldwasser
Publicado 2012